Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib-Reference-Cited by-同舟云学术

Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib

Published:2014-06-12 Issue:24 Volume:370 Page:2286-2294
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Woyach Jennifer A.,Furman Richard R.,Liu Ta-Ming,Ozer Hatice Gulcin,Zapatka Marc,Ruppert Amy S.,Xue Ling,Li Daniel Hsieh-Hsin,Steggerda Susanne M.,Versele Matthias,Dave Sandeep S.,Zhang Jenny,Yilmaz Ayse Selen,Jaglowski Samantha M.,Blum Kristie A.,Lozanski Arletta,Lozanski Gerard,James Danelle F.,Barrientos Jacqueline C.,Lichter Peter,Stilgenbauer Stephan,Buggy Joseph J.,Chang Betty Y.,Johnson Amy J.,Byrd John C.

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1400029

Cited by 1057 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pre-existing cardiovascular disease is associated with an increased risk of cardiovascular events during Bruton tyrosine kinase inhibitor therapy;The Oncologist;2024-09-08

2. A fresh look at covalent BTK inhibitor resistance;Blood;2024-09-05

3. Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib;Blood;2024-09-05

4. Design, synthesis and antitumor activity of a novel FGFR2-selective degrader to overcome resistance of the FGFR2V564F gatekeeper mutation based on a pan-FGFR inhibitor;European Journal of Medicinal Chemistry;2024-09

5. Exosomal miR-155-5p drives ibrutinib resistance in B-cell lymphoma;Experimental Cell Research;2024-09